--- title: "Medical Innovation ETF Ping An is in a tug-of-war, with a flurry of positive news landing for brain-computer interface related companies" type: "News" locale: "en" url: "https://longbridge.com/en/news/279875621.md" description: "The medical innovation ETF is in a stalemate, with frequent positive news emerging from companies related to brain-computer interfaces. The CSI Medical and Medical Device Innovation Index rose by 0.21%, and constituent stocks performed well. Bonree's NEO system received the world's first registration certificate for an invasive brain-computer interface, and JieTi Medical completed a financing of 500 million yuan, marking a new stage in industry development. With policy support, the number of approved domestic new drugs has reached a record high, and the pharmaceutical industry is accelerating the construction of a modernized system" datetime: "2026-03-20T02:19:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279875621.md) - [en](https://longbridge.com/en/news/279875621.md) - [zh-HK](https://longbridge.com/zh-HK/news/279875621.md) --- # Medical Innovation ETF Ping An is in a tug-of-war, with a flurry of positive news landing for brain-computer interface related companies As of March 20, 2026, 10:00 AM, the CSI Pharmaceutical and Medical Device Innovation Index (931484) rose by 0.21%. The constituent stocks include Dong'e Ejiao, which increased by 7.07%, China Resources Sanjiu, which rose by 1.34%, Aier Eye Hospital, which went up by 1.29%, Huatai Medical, which gained 1.05%, and WuXi AppTec, which increased by 0.97%. The Medical Innovation ETF Ping An (516820) is in a tug-of-war between bulls and bears, with the latest quote at 0.35 yuan. In terms of news, there have been a series of positive developments for companies related to brain-computer interfaces recently. Bonree's NEO system has won the world's first Class III medical device registration certificate for invasive brain-computer interfaces, Jielin Medical has completed a strategic financing of 500 million yuan, and the regulatory approval framework is gradually becoming clearer, with key progress in clinical applications. Industry insiders believe that under the triple resonance of policy support, technological breakthroughs, and increased capital, this sector will accelerate its transition from the R&D phase to the commercialization phase, with upstream and downstream enterprises in the industry chain simultaneously entering a golden window period for product validation and market expansion, marking a new stage of quality improvement and acceleration in industrial development. The "14th Five-Year Plan" has for the first time listed biomedicine as a new pillar industry of the country, marking a historic leap in the strategic positioning of industrial development. Galaxy Securities points out that the industry's development is shifting from a scale expansion type of "system construction" to a quality-oriented type of "strengthening the foundation and collaborative governance," with the core driving force being the "three medical linkages" moving from individual departmental reforms to systematic collaborative governance, and the service model shifting from "disease-centered" to "health-centered." With comprehensive policy support, the number of approved domestic Class I new drugs continues to reach new highs, the transaction amount and down payment for BD overseas have significantly increased, the upstream of life sciences and high-end equipment are accelerating domestic substitution, and AI technology is deeply empowering R&D, diagnosis, and service across all scenarios. The pharmaceutical industry is accelerating the construction of a modern system that is self-controllable and has global influence. The Medical Innovation ETF Ping An closely tracks the CSI Pharmaceutical and Medical Device Innovation Index, which selects 30 publicly listed companies with good profitability, certain growth potential, and R&D innovation capabilities from the pharmaceutical and healthcare industry as index samples to reflect the overall performance of publicly listed pharmaceutical and medical device companies that combine profitability and growth. Data shows that as of February 27, 2026, the top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, Pian Zai Huang, New Hope Liuhe, East China Pharmaceutical, Kanglonghua Cheng, Aier, and Dong'e Ejiao, with the top ten weighted stocks accounting for a total of 63.75%. Risk Warning: Funds carry risks, and investments should be made cautiously. The fund manager promises to manage and utilize fund assets based on the principles of honesty, credit, diligence, and responsibility, but does not guarantee that this fund will definitely make a profit, nor does it guarantee a minimum return. The fund manager reminds investors of the "buyer bears the risk" principle in fund investments; after making investment decisions, the investment risks arising from the fund's operating status and changes in net value are borne by the investors themselves. The past performance of the fund and its net value does not indicate its future performance, and the performance of other funds managed by the fund manager does not constitute a guarantee of this fund's performance Investors purchasing funds may share in the profits generated by the fund's investments according to their held shares, but they may also bear the losses arising from the fund's investments. Investors should carefully read the "Fund Contract," "Prospectus," and other legal documents related to the fund to fully understand the risk-return characteristics and product features of the fund. They should assess whether the fund aligns with their risk tolerance based on their investment objectives, investment horizon, investment experience, and asset status, make rational market judgments, and make investment decisions cautiously. The relevant information in this material comes from publicly available sources deemed reliable by the fund manager, and the related opinions, assessments, and forecasts reflect current judgments that may change in the future. Any market opinions contained in this material are based on corresponding assumptions, and any assumptions may change at any time. The fund manager does not promise or guarantee that any predictive market opinions will necessarily be realized. The individual stocks mentioned in the material do not constitute investment recommendations or advice. The fluctuations in the secondary market of ETF funds do not represent the actual return rate of the fund; investors should pay attention to the risks of price volatility in the market ### Related Stocks - [688229.CN](https://longbridge.com/en/quote/688229.CN.md) - [688246.CN](https://longbridge.com/en/quote/688246.CN.md) - [000991.CN](https://longbridge.com/en/quote/000991.CN.md) - [02407.HK](https://longbridge.com/en/quote/02407.HK.md) - [301363.CN](https://longbridge.com/en/quote/301363.CN.md) ## Related News & Research - [Genertec Universal Medical Unit to Issue RMB500 Million Onshore Notes to Refinance Debt](https://longbridge.com/en/news/283805114.md) - [Cofinimmo Posts 8.3% Rise in Earnings Despite Rental Growth Slowing](https://longbridge.com/en/news/283652407.md) - [15:37 ETBGL Announces the Sale of the Louisville Orthopaedic Clinic Real Estate Portfolio](https://longbridge.com/en/news/283549667.md) - [Integrated Diagnostics Publishes 2025 Annual Report and Sets 2026 AGM Date](https://longbridge.com/en/news/283830117.md) - [ZAWYA: Gulf Medical University earns prestigious world physiotherapy accreditation](https://longbridge.com/en/news/283631524.md)